News

The new data indicate that patients who continued to receive denufosol for an additional 24 weeks during the open-label extension experienced a progressive improvement in forced expiratory volume

According to the company, the median number of aura attacks was reduced by 68% (p=0.01) in patients receiving tonabersat when compared with placebo. This result in the primary

The supplemental new drug application (sNDA) submission is supported by a Phase III single-blinded controlled study conducted in Japanese women with no or irregular ovulation, including polycystic ovary

BioCancell is a biopharmaceuticals corporation specializing in the development of patient-oriented, targeted therapy for the treatment of numerous types of cancer. Products under the agreement will be manufactured

The filing is supported by data from three placebo-controlled clinical trials in patients with epilepsy. Previously, Johnson & Johnson Pharmaceutical Research & Development (J&JPRD) and SK Holdings have

Third quarter 2008 net sales from continuing operations were $5.3 billion, an increase of 14%, including a 3% favorable foreign exchange impact, as compared to the corresponding quarter

Since the start of the commercialization of Acomplia, Sanofi-Aventis said that it has been closely collaborating with both the regulatory authorities and healthcare providers to monitor on an

Mr Kogod currently serves as DaVita’s president-west, a role he has occupied since October 2005. Mr Mello, who served as COO since June 2000, will continue with the

Alcon Research Limited (ARL) is an affiliate of Alcon Inc, an eye care company. The alliance combines Origenis’s capabilities in compound design, chemical synthesis, and screening with Alcon’s